SM-88 therapy in patients with advanced or metastatic pancreatic cancer.

457Background: SM-88 (tyrosine derivative, mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively non-toxic, targeted therapy that utilizes the Warburg Effect in combination with oxidative stress to cause tumor cell death. Previously reported results (Phase I and preliminary Phase II) showed safety and efficacy for SM-88 in metastatic and recurrent cancers. Pancreatic cancer continues to have a poor prognosis with toxic standard of care (SOC) therapies, associated serious adverse events (SAEs), and QOL degradation. SM-88 is being evaluated as a minimally toxic alternative treatment. Methods: Retrospective chart review between 2012-17 of 12 patients with advanced or metastatic pancreatic cancer treated with SM-88 through a Phase 1 study (3/12) or compassionate use (9/12) with 10/12 evaluable. Although treatment regimens specifics varied, all were provided SM-88 therapy five days a week, administered by clinicians, orally or through subcutaneous injection; 7/10 patients received SM-88...